Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ZYXI 
Zynex Inc (ZYXI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: ZYXI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.85
1 Year Target Price $2.85
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.02% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.30M USD | Price to earnings Ratio - | 1Y Target Price 2.85 |
Price to earnings Ratio - | 1Y Target Price 2.85 | ||
Volume (30-day avg) 3 | Beta 1.1 | 52 Weeks Range 1.23 - 9.42 | Updated Date 10/17/2025 |
52 Weeks Range 1.23 - 9.42 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-10-23 | When - | Estimate -0.1567 | Actual - |
Profitability
Profit Margin -19.79% | Operating Margin (TTM) -46.13% |
Management Effectiveness
Return on Assets (TTM) -12.11% | Return on Equity (TTM) -168.22% |
Valuation
Trailing PE - | Forward PE 16.61 | Enterprise Value 98848290 | Price to Sales(TTM) 0.28 |
Enterprise Value 98848290 | Price to Sales(TTM) 0.28 | ||
Enterprise Value to Revenue 0.68 | Enterprise Value to EBITDA 20.66 | Shares Outstanding 30297442 | Shares Floating 15700437 |
Shares Outstanding 30297442 | Shares Floating 15700437 | ||
Percent Insiders 48.31 | Percent Institutions 18.27 |
Upturn AI SWOT
Zynex Inc
Company Overview
History and Background
Zynex, Inc. was founded in 1996. The company designs, manufactures, and markets medical devices intended for pain management, rehabilitation, and neurological diagnosis.
Core Business Areas
- Pain Management: Develops and markets electrotherapy devices, such as the NeuroMove and E-Wave, for pain relief and rehabilitation.
- Rehabilitation: Offers devices and supplies to aid in physical therapy and rehabilitation.
- Neurological Monitoring: Manufactures and sells devices for EMG and EEG diagnostic purposes.
Leadership and Structure
Thomas Sandgaard is the Chairman, President, and CEO. The company operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- NeuroMove: A functional electrical stimulation (FES) system used for stroke rehabilitation and pain management. Market share data is not precisely quantifiable. Competitors include companies offering similar FES devices, such as Bioness and Ottobock.
- E-Wave: An electrotherapy device for pain relief. Market share data is not precisely quantifiable. Competitors include companies offering TENS units and similar electrotherapy devices, such as Omron and Roscoe Medical.
- CM-1500: A blood volume monitor. Data on users and revenue is not precisely quantifiable. Competitors include Masimo and Edwards Lifesciences
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulatory scrutiny, and competition. Growing aging population increases demand for pain management and rehabilitation solutions.
Positioning
Zynex Inc. is a niche player focusing on non-invasive pain management and rehabilitation solutions. Their competitive advantage lies in their direct sales force and integrated product offerings.
Total Addressable Market (TAM)
The electrotherapy and rehabilitation market is estimated in the billions of dollars. Zynex is positioned to capture a portion of this TAM through product innovation and market penetration.
Upturn SWOT Analysis
Strengths
- Direct sales force
- Integrated product offerings
- Strong brand recognition in certain segments
- Proprietary technology
Weaknesses
- Limited financial resources compared to larger competitors
- Reliance on a few key products
- Susceptibility to regulatory changes
- Smaller market share compared to market leaders
Opportunities
- Expansion into new markets
- Development of new products
- Strategic partnerships and acquisitions
- Increased awareness of non-pharmacological pain management
Threats
- Increased competition
- Changes in reimbursement policies
- Product liability lawsuits
- Technological obsolescence
Competitors and Market Share
Key Competitors
- BION
- MASI
- EW
Competitive Landscape
Zynex faces competition from larger medical device companies with greater resources. However, its direct sales force and targeted product offerings provide a competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Historical Growth data needs to be populated with real data.
Future Projections: Future Projections data needs to be populated with real data.
Recent Initiatives: Recent Initiatives data needs to be populated with real data.
Summary
Zynex Inc. is a smaller player in the medical device market focused on pain management and rehabilitation. Its direct sales force is a strength, but limited financial resources and competition pose challenges. Expanding into new markets and developing innovative products are crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market data may vary and is subject to change. The AI rating is based on limited publicly available information and should not be the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zynex Inc
Exchange NASDAQ | Headquaters Englewood, CO, United States | ||
IPO Launch date 2002-12-31 | CEO - | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 1000 | Website https://www.zynex.com |
Full time employees 1000 | Website https://www.zynex.com | ||
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.